Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2014. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive compensation and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction regarding the GSK Deferred Annual Bonus Plan for Ms. C Thomas on May 7, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports the exercise of nil-priced options over 1,967 shares and 783 shares granted on February 24, 2011, which vested on February 24, 2014. Ms. Thomas is scheduled to receive a cash payment for 2,750 shares net of tax on May 20, 2014.
Investor Verification Checklist
- Verify the total number of shares vested and the corresponding cash payout for Ms. C Thomas.
- Confirm the vesting date of the options (February 24, 2014) versus the transaction notification date (May 7, 2014).
- Review the GSK Deferred Annual Bonus Plan terms to understand the nil-priced option structure.
- Note that this filing does not replace or update the company's quarterly or annual financial reports.